JLPC(SH:600513)2022-04-27 16:00Financial Performance - The company's operating revenue for 2021 was CNY 1,645,816,399.14, representing an increase of 18.74% compared to CNY 1,386,038,580.46 in 2020[20] - The net profit attributable to shareholders for 2021 was CNY 118,839,366.34, up 15.38% from CNY 103,001,877.67 in 2020[20] - The net cash flow from operating activities increased by 50.48% to CNY 138,344,527.41 in 2021, compared to CNY 91,936,547.95 in 2020[20] - The total assets of the company at the end of 2021 were CNY 2,354,796,481.05, a 14.92% increase from CNY 2,049,066,254.48 at the end of 2020[20] - The basic earnings per share for 2021 were CNY 0.41, reflecting a 13.89% increase from CNY 0.36 in 2020[21] - The weighted average return on equity for 2021 was 10.71%, an increase of 0.67 percentage points from 10.04% in 2020[21] - The operating profit for 2021 was 156 million RMB, an increase of 9.10% compared to the previous year[53] - The net profit attributable to the parent company was 119 million RMB, reflecting a year-on-year growth of 15.38%[53] Dividend and Shareholder Information - The company plans to distribute a cash dividend of CNY 1.25 per 10 shares, totaling CNY 35,893,209.25, subject to shareholder approval[5] - The annual shareholders' meeting held on April 26, 2021, had a total of 111,632,688 shares represented, accounting for 38.76% of the total shares[118] - The total pre-tax remuneration for the board members and senior management during the reporting period amounted to 924.87 million yuan[119] - The company has a clear cash dividend distribution standard and decision-making process, with independent directors fulfilling their responsibilities[146] Research and Development - The company launched 18 new products and completed clinical trials for innovative drug LH-1801 in 2021[30] - The company applied for 2 international invention patents and 4 domestic invention patents in 2021, enhancing its intellectual property portfolio[30] - The company has a strong R&D capability with key research platforms in Yangzhou and Nanjing, focusing on high-quality projects[48] - The company invested ¥85,006,700 in R&D, accounting for 5.17% of total revenue, which is a 45.11% increase compared to the previous year[84] - The company has significant ongoing R&D projects, including an innovative anti-diabetic drug with an investment of 21,087,065.17 RMB, showing a year-on-year increase of 839.49%[92] Market and Sales Performance - Sales volume of the product "Teva" increased by 57.12% year-on-year, reaching 12.7 million units sold[34] - The subsidiary Yangzhou Lianhuan Pharmaceutical achieved sales revenue of 533 million RMB, a year-on-year increase of 47.62%[34] - The company reported a 49.78% increase in revenue from medical devices, contributing to overall revenue growth[59] - The company’s sales network for its formulation products covers the entire country, with sales offices established in key provinces and cities[40] Risk Management and Compliance - The company reported no significant risks that could materially affect its operations during the reporting period[8] - The company does not have any non-operating fund occupation by controlling shareholders or related parties[7] - The company has established a comprehensive quality management system to mitigate risks associated with product quality during production and sales[110] - The company has not experienced any leakage of insider information during the reporting period, ensuring compliance with confidentiality obligations[115] Environmental Responsibility - The company has reported zero administrative penalties related to environmental issues during the reporting period[161] - The company has implemented multiple pollution control facilities, including a boiler exhaust emission point that has been operational since 2013, ensuring compliance with environmental standards[155] - The company has a robust emergency response plan for environmental incidents, which was published and implemented in April 2021[158] - The company has achieved compliance in hazardous waste disposal by partnering with certified waste disposal companies[166] Corporate Governance - The board of directors has established specialized committees to oversee strategic, nomination, audit, and compensation matters, ensuring compliance with regulations[113] - The company has a performance evaluation and incentive mechanism for senior management, aligning their interests with shareholder value[114] - The company emphasizes the importance of effective communication with shareholders and has implemented measures to ensure transparency and fairness in governance[112] - The company has committed to maintaining independent business operations, ensuring that it has the necessary assets, personnel, and capabilities to operate autonomously[117] Strategic Initiatives - The company aims to enhance its R&D capabilities and accelerate new product development, focusing on both short-term and long-term product lines[103] - The company is investing in multiple projects, including a solid preparation construction project with a total investment commitment of 21,111,000 RMB, of which 134.18 million RMB has been invested this year[97] - The company is expanding its market presence in Southeast Asia, targeting a 30% market share within the next two years[120] - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the biotechnology sector[124]